• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: rituximab and recombinant human hyaluronidase
Trade Name: Rituxan SC
Date Designated: 09/07/2016
Orphan Designation: Treatment of diffuse large B-cell lymphoma
Orphan Designation Status: Designated/Approved
Genentech, Inc.
1 DNA Way
South San Francisco, California 94080
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: rituximab and recombinant human hyaluronidase
Trade Name: Rituxan SC
Marketing Approval Date: 06/22/2017
Approved Labeled Indication: Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
Exclusivity End Date: 06/22/2024 
Exclusivity Protected Indication* :  Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-